skip to main content
Idioma:

Recent advances in nanocarriers for clinical platinum(II) anticancer drugs

Zhang, Jing-Jing ; Xu, Qi-Jie ; Zhang, Yue ; Zhou, Qichen ; Lv, Rui ; Chen, Zhen ; He, Weijiang

Coordination chemistry reviews, 2024-04, Vol.505, Article 215676 [Periódico revisado por pares]

Elsevier B.V

Texto completo disponível

Citações Citado por
  • Título:
    Recent advances in nanocarriers for clinical platinum(II) anticancer drugs
  • Autor: Zhang, Jing-Jing ; Xu, Qi-Jie ; Zhang, Yue ; Zhou, Qichen ; Lv, Rui ; Chen, Zhen ; He, Weijiang
  • Assuntos: Constructions ; Drug resistance ; Nanocarriers ; Platinum(II) anticancer drugs ; Toxic effects
  • É parte de: Coordination chemistry reviews, 2024-04, Vol.505, Article 215676
  • Descrição: [Display omitted] •Nanocarriers specifically developed for clinical platinum(II) anticancer drugs in the last five years are comprehensively summarized.•Nanocarries for clinical platinum(II) anticancer drugs are systematically classified.•The construction of each kind of nanocarriers for clinical platinum(II) anticancer drugs is described in detail.•The accomplishments of each newly developed nanocarriers for clinical platinum(II) anticancer drugs are discussed.•Future efforts for more smart delivery of clinical platinum(II) anticancer drugs are proposed. Platinum(II) drugs have been one of the most commonly used anticancer drugs in clinic. However, drug resistance and severe toxic effects limit their clinical applications. Developing nanocarriers for platinum(II) anticancer drugs provides promising strategies to overcome these problems, ascribed to their versatile functionalities such as precise delivery of platinum(II) drugs to tumor site, modulation of tumor microenvironment, and integration of other anticancer agents or therapies. In this review, nanocarriers that have been recently developed to deliver platinum(II) anticancer drugs in the last five years are described focusing on their smart constructions and functions. The current situation of clinical platinum(II) anticancer drugs is first introduced, followed by the discussion of the irreplaceable role of nanocarriers for platinum(II) anticancer drugs. Afterward, the rules for classifying the nanocarriers in this review and the advantages of each type are explained. Based on the classification, the latest published nanocarriers of each kind for platinum(II) drugs are then described in detail. In the end, conclusions and future directions provide perspectives for future exploration of more smart delivery strategies for platinum(II) drugs. It is expected that this review will promote the development of more efficient and safe nanocarriers for platinum(II) anticancer drugs that are available for the final clinical application.
  • Editor: Elsevier B.V
  • Idioma: Inglês
Voltar para lista de resultados

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.